Evaluation of Overactive Bladder Symptoms in Patients Recovering from Post-Acute COVID-19 Syndrome.
AUA-OAB tool
nocturia
overactive bladder
post-acute COVID-19
quality of life
Journal
Journal of multidisciplinary healthcare
ISSN: 1178-2390
Titre abrégé: J Multidiscip Healthc
Pays: New Zealand
ID NLM: 101512691
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
08
2022
accepted:
18
10
2022
entrez:
2
11
2022
pubmed:
3
11
2022
medline:
3
11
2022
Statut:
epublish
Résumé
Coronavirus disease (COVID-19) is a multi-organ viral infection with many manifestations. However, its impact on the genitourinary system is nowadays under investigation. This study aimed to evaluate the consequences on bladder function in patients suffering from post-acute COVID-19 syndrome (PACS) transferred to inpatient rehabilitation for long-term care after initial treatment for COVID-19 pathophysiology. All the patients were initially asked the question (after having recovered from the acute stage of COVID-19 disease): "Have you noticed a sudden, uncontrolled need to urinate and sometimes a urine leakage accompanying the voiding desire?" Sixty-six out of 147 patients responded positively to this question and were assessed with the AUA Urology Care Foundation Overactive Bladder Assessment Tool (AUA-OAB-tool). All included men were evaluated with the IPSS score. The median age of patients was 59.5 (range 44-72). We identified 44 patients with newly diagnosed OAB (Group A; post-COVID assessment) and 22 with worsening OAB symptoms (Group B). The mean symptom score ± standard deviation in Group A patients was 18.25 ± 2.11 (using the above AUA OAB tool). In the patients of Group B, there was an increase in the above score from 10.43 ± 1.52 (pre-COVID condition) to 17.87 ± 1.89 (post-COVID assessment). In patients of Group A, the total quality of life (QOL) score was 17.74 ± 2.34. Patients in Group B presented an escalation in total QOL score from 9.04 ± 1.41 (pre-COVID) to 18.84 ± 1.96 (post-COVID condition). There was no statistically significant difference in symptoms and QOL scores between men and women in groups A and B. There were 11 men in Group A and 5 in Group B with an IPSS score >20. OAB symptoms may be essential to PACS syndrome and influence quality of life, delaying full recovery.
Identifiants
pubmed: 36320554
doi: 10.2147/JMDH.S384436
pii: 384436
pmc: PMC9618246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2447-2452Informations de copyright
© 2022 Zachariou et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Med Hypotheses. 2020 Dec;145:110375
pubmed: 33213997
Neurology. 2020 May 12;94(19):809-810
pubmed: 32229625
Neurourol Urodyn. 2021 Jun;40(5):1200-1206
pubmed: 33942372
Urol J. 2020 Sep 05;17(5):433-441
pubmed: 32888186
Pract Neurol. 2017 Jan;17(1):79-80
pubmed: 27903765
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Int J Clin Pract. 2021 Jun;75(6):e14110
pubmed: 33621391
Eur Urol. 2020 Sep;78(3):e129-e130
pubmed: 32591102
Low Urin Tract Symptoms. 2022 Jul;14(4):301-304
pubmed: 35293147
Int J Clin Pract. 2021 Mar;75(3):e13850
pubmed: 33222353
J Clin Med Res. 2020 Oct;12(10):681-682
pubmed: 33029276
Eur Urol. 2020 Oct;78(4):624-628
pubmed: 32475747
J Prev Med Hyg. 2020 Oct 06;61(3):E304-E312
pubmed: 33150219
Eur Urol. 2020 Jul;78(1):e40-e41
pubmed: 32345522
J Med Virol. 2021 May;93(5):3133-3142
pubmed: 33595134
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937